Brief: Sellas Gets Green Light to Continue Phase 3 REGAL Trial of GPS in AML After Positive Data Review
07/08/2025 13:51
Aug 7 (Reuters) - Sellas Life Sciences Group Inc SLS.O: SELLAS LIFE SCIENCES ANNOUNCES INDEPENDENT DATA MONITORING COMMITTEE PERIODIC REVIEW AND POSITIVE RECOMMENDATION TO CONTINUE PIVOTAL PHASE 3 REGAL TRIAL OF GPS IN AML WITHOUT MODIFICATION SELLAS LIFE SCIENCES GROUP INC - IDMC FINDS NO SAFETY CONCERNS IN GPS TRIAL SELLAS LIFE SCIENCES GROUP INC: FINAL ANALYSIS ANTICIPATED BY YEAR-END UPON OCCURRENCE OF 80 EVENTS Source text: ID:nGNX47xTHB Further company coverage: SLS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses